Hirobriz Breezhaler

RSS

Withdrawn

This medicine's authorisation has been withdrawn

indacaterol
MedicineHumanWithdrawn

Romanian is available via eTranslation, the European Commission's machine translation service.

Translate to Romanian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 30 October 2026, the European Commission withdrew the marketing authorisation for Hirobriz Breezhaler (indacaterol) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Novartis Europharm Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Hirobriz Breezhaler was granted marketing authorisation in the EU on 30 November 2009 for the treatment of chronic obstructive pulmonary disease (COPD). The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Hirobriz Breezhaler was a duplicate of Onbrez Breezhaler, which is marketed in several EU countries. The withdrawal of Hirobriz Breezhaler is not expected to have any impact on patient access to treatment, as the corresponding reference product, Onbrez Breezhaler, remains authorised and available on the market.

български (BG) (142.1 KB - PDF)

Vizualizare

español (ES) (111.41 KB - PDF)

Vizualizare

čeština (CS) (137.16 KB - PDF)

Vizualizare

dansk (DA) (110.8 KB - PDF)

Vizualizare

Deutsch (DE) (112.08 KB - PDF)

Vizualizare

eesti (ET) (117.23 KB - PDF)

Vizualizare

ελληνικά (EL) (144.38 KB - PDF)

Vizualizare

français (FR) (111.95 KB - PDF)

Vizualizare

hrvatski (HR) (132.95 KB - PDF)

Vizualizare

italiano (IT) (110.63 KB - PDF)

Vizualizare

latviešu (LV) (135.24 KB - PDF)

Vizualizare

lietuvių (LT) (135.44 KB - PDF)

Vizualizare

magyar (HU) (132.88 KB - PDF)

Vizualizare

Malti (MT) (174.53 KB - PDF)

Vizualizare

Nederlands (NL) (110.63 KB - PDF)

Vizualizare

polski (PL) (137.93 KB - PDF)

Vizualizare

português (PT) (111.57 KB - PDF)

Vizualizare

română (RO) (134.35 KB - PDF)

Vizualizare

slovenčina (SK) (137.6 KB - PDF)

Vizualizare

slovenščina (SL) (131.52 KB - PDF)

Vizualizare

suomi (FI) (110.26 KB - PDF)

Vizualizare

svenska (SV) (110.95 KB - PDF)

Vizualizare

Product information

български (BG) (836.29 KB - PDF)

Vizualizare

español (ES) (750.94 KB - PDF)

Vizualizare

čeština (CS) (818.08 KB - PDF)

Vizualizare

dansk (DA) (768.28 KB - PDF)

Vizualizare

Deutsch (DE) (770.67 KB - PDF)

Vizualizare

eesti (ET) (762.26 KB - PDF)

Vizualizare

ελληνικά (EL) (828.22 KB - PDF)

Vizualizare

français (FR) (786.68 KB - PDF)

Vizualizare

hrvatski (HR) (760.77 KB - PDF)

Vizualizare

italiano (IT) (790.56 KB - PDF)

Vizualizare

latviešu (LV) (756.08 KB - PDF)

Vizualizare

lietuvių (LT) (790.92 KB - PDF)

Vizualizare

magyar (HU) (796.09 KB - PDF)

Vizualizare

Malti (MT) (861.04 KB - PDF)

Vizualizare

Nederlands (NL) (739.71 KB - PDF)

Vizualizare

polski (PL) (839.39 KB - PDF)

Vizualizare

português (PT) (772.58 KB - PDF)

Vizualizare

română (RO) (807.04 KB - PDF)

Vizualizare

slovenčina (SK) (823.98 KB - PDF)

Vizualizare

slovenščina (SL) (775.5 KB - PDF)

Vizualizare

suomi (FI) (739.22 KB - PDF)

Vizualizare

svenska (SV) (758.79 KB - PDF)

Vizualizare

Íslenska (IS) (804.55 KB - PDF)

Vizualizare

norsk (NO) (741.04 KB - PDF)

Vizualizare
Latest procedure affecting product information:VR/0000308592
18/11/2025
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (102.06 KB - PDF)

Vizualizare

español (ES) (27.75 KB - PDF)

Vizualizare

čeština (CS) (95.76 KB - PDF)

Vizualizare

dansk (DA) (28.23 KB - PDF)

Vizualizare

Deutsch (DE) (27.98 KB - PDF)

Vizualizare

eesti (ET) (28.37 KB - PDF)

Vizualizare

ελληνικά (EL) (97.94 KB - PDF)

Vizualizare

français (FR) (28.14 KB - PDF)

Vizualizare

hrvatski (HR) (43.79 KB - PDF)

Vizualizare

italiano (IT) (27.64 KB - PDF)

Vizualizare

latviešu (LV) (95.5 KB - PDF)

Vizualizare

lietuvių (LT) (95.93 KB - PDF)

Vizualizare

magyar (HU) (57.54 KB - PDF)

Vizualizare

Malti (MT) (99.59 KB - PDF)

Vizualizare

Nederlands (NL) (27.55 KB - PDF)

Vizualizare

polski (PL) (97.28 KB - PDF)

Vizualizare

português (PT) (27.95 KB - PDF)

Vizualizare

română (RO) (94.23 KB - PDF)

Vizualizare

slovenčina (SK) (95.86 KB - PDF)

Vizualizare

slovenščina (SL) (27.56 KB - PDF)

Vizualizare

suomi (FI) (27.62 KB - PDF)

Vizualizare

svenska (SV) (27.98 KB - PDF)

Vizualizare

Íslenska (IS) (33.04 KB - PDF)

Vizualizare

norsk (NO) (32.9 KB - PDF)

Vizualizare

Product details

Name of medicine
Hirobriz Breezhaler
Active substance
indacaterol maleate
International non-proprietary name (INN) or common name
indacaterol
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
R03AC18

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

Authorisation details

EMA product number
EMEA/H/C/001211
Marketing authorisation holder
Novartis Europharm Limited

Vista Building
Elm Park
Merrion Road
Dublin 4
D04 A9N6
Ireland

Opinion adopted
24/09/2009
Marketing authorisation issued
30/11/2009
Withdrawal of marketing authorisation
30/10/2026
Revision
21

Assessment history

This page was last updated on

Share this page